The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs
Status:
Not yet recruiting
Trial end date:
2026-11-25
Target enrollment:
Participant gender:
Summary
This is a prospective non-randomized national clinical phase 2 trial that aims to determine
the efficacy and toxicity of commercially available EMA approved targeted anticancer drugs or
combinations for treatment of patients with advanced cancer with a potentially actionable
variant as revealed by a genomic, RNA-molecular or protein expression test.